Literature DB >> 31587941

Right ventricle and outcome in left ventricular non-compaction cardiomyopathy.

Simon F Stämpfli1, Thierry G Donati2, Jens Hellermann3, Shehab Anwer2, Ladina Erhart2, Christiane Gruner2, Beat A Kaufmann4, Baris Gencer5, Philipp K Haager6, Hajo Müller5, Felix C Tanner7.   

Abstract

BACKGROUND: The risk of adverse events in patients with left ventricular non-compaction cardiomyopathy (LVNC) is substantial. Information on prognostic factors, however, is limited. This study was designed to assess the prognostic value of right ventricular (RV) size and function in LVNC patients.
METHODS: Cox regression analyses were used to determine the association of indexed RV end-diastolic area (RV-EDAI), indexed end-diastolic diameter (RV-EDDI), fractional area change (FAC), and tricuspid annular systolic excursion (TAPSE) with the occurrence of death or heart transplantation (composite endpoint).
RESULTS: Out of 127 patients (53.2 ± 17.8 years; 61% males, median follow-up time was 7.7 years), 17 patients reached the endpoint. In a univariate analysis, RV-EDAI was the strongest predictor of outcome [HR 1.48 (1.24-1.77) per cm2/m2; p < 0.0001]. FAC was predictive as well [HR 1.44 (1.16-1.83) per 5% decrease; p = 0.0009], while TAPSE was not (p=ns). RV-EDAI remained an independent predictor in a bivariable analysis with indexed left ventricular ED volume [HR 1.41 (1.18-1.70) per cm2/m2; p = 0.0002], while analysis of FAC and left ventricular ejection fraction demonstrated that FAC was not independent [HR 1.20 (0.98-1.52); per 5% decrease; p = 0.0721]. RV-EDAI 11.5 cm2/m2 was the best cut-off value for separating patients in terms of outcome. Patients with RV-EDAI >11.5 cm2/m2 had a survival rate of 18.5% over 12 years as compared to 93.8% in patients with RV-EDAI <11.5 cm2/m2 (p < 0.0001).
CONCLUSION: Increased end-diastolic RV size and decreased systolic RV function are predictors of adverse outcome in patients with LVNC. Patients with RV-EDAI >11.5 cm2/m2 exhibit a significantly lower survival than those <11.5 cm2/m2.
Copyright © 2019 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Echocardiography; End-diastolic area; Fractional area change; Prognosis; Survival; Trabeculation

Year:  2019        PMID: 31587941     DOI: 10.1016/j.jjcc.2019.09.003

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  6 in total

1.  Tricuspid Annular Abnormalities in Isolated Left Ventricular Non-compaction-Insights From the Three-dimensional Speckle-Tracking Echocardiographic MAGYAR-Path Study.

Authors:  Attila Nemes; Gergely Rácz; Árpád Kormányos
Journal:  Front Cardiovasc Med       Date:  2022-05-25

2.  Impact of Right Ventricular Trabeculation on Right Ventricular Function in Patients With Left Ventricular Non-compaction Phenotype.

Authors:  Anna Réka Kiss; Zsófia Gregor; Adrián Popovics; Kinga Grebur; Liliána Erzsébet Szabó; Zsófia Dohy; Attila Kovács; Bálint Károly Lakatos; Béla Merkely; Hajnalka Vágó; Andrea Szũcs
Journal:  Front Cardiovasc Med       Date:  2022-04-12

3.  Influence of Right Ventricular Dysfunction on Outcomes of Left Ventricular Non-compaction Cardiomyopathy.

Authors:  Wuwan Wang; Wei Chen; Xue Lin; Ligang Fang
Journal:  Front Cardiovasc Med       Date:  2022-01-31

Review 4.  A Systematic Review of Ebstein's Anomaly with Left Ventricular Noncompaction.

Authors:  Suma K Thareja; Michele A Frommelt; Joy Lincoln; John W Lough; Michael E Mitchell; Aoy Tomita-Mitchell
Journal:  J Cardiovasc Dev Dis       Date:  2022-04-13

Review 5.  Cardiac Imaging in Athlete's Heart: The Role of the Radiologist.

Authors:  Marco Fogante; Giacomo Agliata; Maria Chiara Basile; Paolo Compagnucci; Giovanni Volpato; Umberto Falanga; Giulia Stronati; Federico Guerra; Davide Vignale; Antonio Esposito; Antonio Dello Russo; Michela Casella; Andrea Giovagnoni
Journal:  Medicina (Kaunas)       Date:  2021-05-07       Impact factor: 2.430

6.  Right ventricular involvement in left ventricular non-compaction cardiomyopathy.

Authors:  Simon F Stämpfli; Alexander Gotschy; Pascal Kiarostami; Tardu Özkartal; Christiane Gruner; Markus Niemann; Robert Manka; Felix C Tanner
Journal:  Cardiol J       Date:  2020-07-10       Impact factor: 3.487

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.